# US Insulin Biosimilars Market

> US Insulin Biosimilars Market Research Report By Type (Rapid-acting biosimilars, Long-acting biosimilars, Premixed biosimilars) and By Indication (TYPE I DIABETES, TYPE II DIABETES) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.31%
- **2024:** $ 1.26 Million
- **2025:** $ 1.35 Million
- **2035:** $ 2.74 Million
- **Key Players:** Sanofi (FR), Boehringer Ingelheim (DE), Mylan (US), Sandoz (CH), Teva (IL), Fresenius Kabi (DE), Celltrion (KR), Amgen (US), Roche (CH)

**Report ID:** MRFR/Pharma/18133-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-insulin-biosimilars-market-19680

---

## Market Summary

## **US Insulin Biosimilars Market Overview**

As per MRFR analysis, the US Insulin Biosimilars Market Size was estimated at 109.69 (USD Million) in 2023. The US Insulin Biosimilars Market Industry is expected to grow from 125.71(USD Million) in 2024 to 530.99 (USD Million) by 2035. The US Insulin Biosimilars Market CAGR (growth rate) is expected to be around 13.995% during the forecast period (2025 - 2035).

### **Key US Insulin Biosimilars Market Trends Highlighted**

The US Insulin Biosimilars Market is experiencing significant growth driven by increasing healthcare costs, a rising prevalence of diabetes, and the demand for affordable treatment options. Insulin biosimilars present an opportunity for cost savings compared to their originator counterparts, making them appealing to patients and healthcare providers alike. The introduction of new biosimilars into the market is also a response to the ongoing push for more affordable medications, which aligns with the broader healthcare reforms initiated by the US government.

Policies aimed at enhancing market access for biosimilars and improving competition are vital market drivers, encouraging innovation and development in this sector.

Recent times have seen a notable trend towards increased acceptance and utilization of insulin biosimilars among healthcare professionals and patients. As doctors gain more confidence in the efficacy and safety of biosimilars, the likelihood of prescription rates rising grows. This acceptance is essential in overcoming historical skepticism surrounding biosimilars and can lead to improved patient adherence to treatment regimens. Furthermore, initiatives focusing on education about biosimilars are creating a more informed patient population, which is critical in fostering trust and addressing concerns.

Opportunities exist to explore collaborations between pharmaceutical companies and healthcare providers to enhance awareness and accessibility of insulin biosimilars.

By facilitating clinical evidence generation and patient education initiatives, stakeholders can drive acceptance and utilization. Additionally, the growth of telemedicine can further support diabetes management, as remote consultations may create avenues for greater discussion around the use of biosimilars. Overall, the US Insulin Biosimilars Market is poised for expansion, given the alignment between patient needs and healthcare policies advocating for more accessible diabetes treatment solutions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Insulin Biosimilars Market Drivers**

### **Rising Prevalence of Diabetes**

The increasing prevalence of diabetes in the United States is a significant driver for the US[Insulin Biosimilars Market](../../../reports/insulin-biosimilars-market-9775) Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 37.3 million Americans, or 11.3% of the population, had diabetes in 2019. This number is expected to rise as lifestyle changes contribute to obesity and other risk factors for diabetes. The American Diabetes Association estimates that the prevalence of diabetes will continue to increase, which will lead to greater demand for insulin and subsequently stimulate the biosimilars market.

As the patient population grows, the need for affordable treatment alternatives such as insulin biosimilars becomes increasingly critical, creating substantial growth opportunities within the US Insulin Biosimilars Market.

### **Cost-Effectiveness of Biosimilars**

The cost-effectiveness of insulin biosimilars compared to their reference biologics presents a strong market driver for the US Insulin Biosimilars Market Industry. Research indicates that biosimilars can save healthcare systems up to 30% in treatment costs compared to branded biologics. The Centers for Medicare and Medicaid Services (CMS) projects annual savings of around USD 54 billion from biologic drugs by 2026 due to the introduction of biosimilars.

These financial benefits appeal to both healthcare providers and patients, encouraging their adoption in the treatment landscape, particularly in high-cost areas such as diabetes management.

### **Increased Research and Development Investment**

Significant investments in Research and Development (R&D) for insulin biosimilars from pharmaceutical companies are driving growth in the US Insulin Biosimilars Market Industry. The Biotechnology Innovation Organization highlights that U.S. biotechnology firms invested around USD 88 billion in R&D in the last year alone, with a substantial portion allocated to developing biosimilars. This investment not only accelerates the innovation of new products but also enhances the understanding of biopharmaceutical manufacturing, ultimately leading to more effective and accessible insulin alternatives.

The focus on R&D is vital as it contributes to the advancement of biosimilar technology and addresses rigorous regulatory requirements in the U.S.

### **Supportive Regulatory Environment**

The regulatory environment in the United States is increasingly supportive of the development and approval of biosimilars, which positively impacts the US Insulin Biosimilars Market Industry. The Food and Drug Administration (FDA) has taken significant steps to streamline the approval process for biosimilars, implementing guidelines to facilitate their entry into the market. In recent years, the FDA has approved a number of biosimilar products, providing assurance to both manufacturers and healthcare providers.

As the pathway for biosimilars becomes clearer and more efficient, it encourages more companies to enter the market, fostering competition and ultimately benefiting patients through greater accessibility and affordability of insulin products.

## **US Insulin Biosimilars Market Segment Insights**

### **Insulin Biosimilars Market Type Insights**

The US Insulin Biosimilars Market is rapidly evolving, with Type serving as a pivotal segment that includes various formulations tailored to meet diverse patient needs. Within this segment, Rapid-acting biosimilars are particularly significant as they offer a quick onset of action, making them essential for postprandial glucose control. These products allow for flexibility in meal timing, critical for individuals managing their diabetes effectively. Long-acting biosimilars also play a crucial role by providing steady insulin levels over an extended period, which is beneficial for maintaining basal insulin needs and reducing the frequency of injections required throughout the day.

The importance of Long-acting biosimilars is underscored by their ability to improve adherence to treatment regimens, thus potentially lowering the long-term complications associated with diabetes. Premixed biosimilars, on the other hand, combine both rapid and long-acting insulins, making them a convenient option for patients who prefer a simplified management approach without having to measure various insulins separately. This ease of use enhances patient compliance and offers a practical solution for glycemic control.

Overall, the segmentation of the US Insulin Biosimilars Market by Type reveals a landscape characterized by innovation and the continuous introduction of products designed to enhance patient outcomes, supported by a growing demand for cost-effective treatment alternatives in the diabetes management arena.

Factors such as the rising prevalence of diabetes in the United States, increasing healthcare costs, and the push for biosimilars as a viable alternative to branded insulins fuel the demand further. This indicates a robust future for the Type segment, reflecting a market transition towards more accessible insulin therapies that can accommodate the diverse needs of patients across the country. The US Insulin Biosimilars Market segmentation not only highlights competitive aspects but also aligns with the ongoing trends of personalized medicine and patient-centered care, which are becoming increasingly important in the healthcare landscape.

Each component within the Type segment presents unique advantages that contribute significantly to patient management strategies while addressing broader healthcare challenges, including affordability and access to necessary treatments.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Insulin Biosimilars Market Indication Insights**

The US Insulin Biosimilars Market focuses on various indications, with Type I and Type II diabetes being the principal categories that drive the market dynamic. Type I diabetes, often diagnosed in childhood, progresses lifelong and requires constant insulin management, fostering a significant demand for biosimilars that can offer cost-effective alternatives to legacy products. Conversely, Type II diabetes has been on the rise, driven by factors such as obesity and sedentary lifestyles, thus increasing the overall market growth potential for biosimilars as more patients enter into treatment regimens.

The growing emphasis on accessible and affordable treatment options underpins the rising significance of biosimilars in both indications, as they serve to improve patient outcomes while managing healthcare expenditures. Moreover, the regulatory landscape in the US, which supports the approval of biosimilars, further enhances the speed-to-market for these alternatives, positioning them as an essential option for both Type I and Type II diabetes management. As these indications encompass a vast portion of the diabetes population in the US, the insights surrounding their treatment options reflect the overarching trend towards innovation and efficacy in diabetes care.

## **US Insulin Biosimilars Market Key Players and Competitive Insights**

The US Insulin Biosimilars Market has been experiencing significant growth driven by the increasing prevalence of diabetes and the rising need for cost-effective treatment options. The integration of biosimilars into the insulin segment is reshaping the competitive landscape, allowing for more affordable therapeutic alternatives that can potentially enhance patient access to necessary medications. As healthcare systems look for ways to reduce expenses without compromising the quality of care, the introduction of insulin biosimilars has become a focal point. This transition is characterized by innovation in drug development and regulatory frameworks that support the entry of biosimilars into the market.

Companies are working tirelessly to establish their presence and differentiate their products in this increasingly competitive environment.

### **Novartis**

Novartis has carved out a significant niche within the US Insulin Biosimilars Market by leveraging its strong research and development capabilities. The company's depth of expertise in the biopharmaceutical sector enables it to effectively navigate the complexities associated with the development and commercialization of biosimilars. Novartis has focused on delivering high-quality products that not only meet regulatory standards but also address patient needs for affordable insulin options. With a strong brand reputation and a commitment to innovation, Novartis is well-positioned in the market.

The company utilizes robust marketing strategies and collaborations with healthcare providers to streamline adoption and ensure its biosimilars gain traction in a competitive space, enhancing its market presence more rapidly.

### **Merck**

Merck has also made notable strides in the US Insulin Biosimilars Market, showcasing a diverse portfolio of products that cater to different patient needs. The company's strength lies in its comprehensive understanding of the diabetes landscape, alongside its ongoing investments in biosimilar research and development. Key products have reflected Merck’s emphasis on quality and efficacy, driving a strong presence in the market. With a commitment to innovation, Merck continually seeks opportunities for mergers and acquisitions that can bolster its competitive edge and expand its capabilities within the biosimilars segment.

The company focuses on leveraging its established distribution networks and partnerships with healthcare institutions to ensure its products reach patients effectively, ultimately contributing to enhanced patient outcomes and affordability in the US insulin treatment arena.

### **Key Companies**

Key Companies in the US Insulin Biosimilars Market Include:

## **US Insulin Biosimilars Market Industry Developments**

Recent developments in the US Insulin Biosimilars Market indicate a growing focus on increasing accessibility to insulin products. In August 2023, Eli Lilly announced the launch of a new biosimilar insulin product, which is aimed at improving affordability for patients. Merck has also been making strides in the market, reflecting a competitive atmosphere as companies strive to innovate and capture market share. Furthermore, Novartis has been actively engaging in partnerships and collaborations to enhance its biosimilar portfolio, signifying an evolving landscape. The market's growth is evident, with valuations surging due to heightened demand for cost-effective diabetes treatments.

In March 2022, the FDA's approval of multiple biosimilar insulin products marked a significant achievement, contributing to increased competition among major players such as Biocon, Sandoz, and Teva.

Additionally, in September 2022, Boehringer Ingelheim and Fresenius Kabi announced a strategic partnership focusing on insulin biosimilars, thereby solidifying their positions in the market. Overall, the competitive dynamics and recent developments reflect a robust evolution of the US Insulin Biosimilars Market, emphasizing innovation and patient-centered approaches.

## **US Insulin Biosimilars Market Segmentation Insights**

### **Insulin Biosimilars Market Type Outlook**

### **Insulin Biosimilars Market Indication Outlook**

## Market Drivers

### Rising Diabetes Prevalence

The increasing incidence of diabetes in the US is a primary driver for the insulin biosimilars market. According to the Centers for Disease Control and Prevention (CDC), approximately 34.2 million people in the US have diabetes, which represents about 10.5% of the population. This growing patient base necessitates a more extensive range of insulin products, including biosimilars, to meet the demand for affordable treatment options. As healthcare costs continue to rise, the insulin biosimilars market is likely to expand, providing patients with more accessible alternatives. Furthermore, the increasing awareness of diabetes management and the importance of insulin therapy is expected to further propel the market, as patients seek effective and cost-efficient solutions for their treatment.

### Cost Containment Initiatives

Cost containment measures implemented by healthcare providers and insurers are significantly influencing the insulin biosimilars market. With the rising costs of diabetes management, stakeholders are increasingly looking for ways to reduce expenses. Biosimilars, which are typically priced lower than their reference biologics, offer a viable solution. The US government has also introduced various policies aimed at reducing drug prices, which may further encourage the adoption of biosimilars. For instance, the introduction of the Affordable Care Act has led to increased scrutiny of drug pricing, prompting insurers to favor lower-cost alternatives. As a result, the insulin biosimilars market is likely to benefit from these initiatives, as patients and providers alike seek more economical treatment options.

### Regulatory Framework Enhancements

The evolving regulatory framework surrounding biosimilars is shaping the insulin biosimilars market. The US Food and Drug Administration (FDA) has established a clear pathway for the approval of biosimilars, which has encouraged manufacturers to invest in this sector. Recent guidelines have streamlined the approval process, making it easier for new entrants to bring their products to market. This regulatory support is crucial, as it fosters innovation and competition within the insulin biosimilars market. Additionally, the FDA's commitment to ensuring the safety and efficacy of biosimilars reassures both healthcare providers and patients, potentially increasing acceptance and utilization of these products. As the regulatory landscape continues to evolve, it is expected that the insulin biosimilars market will experience further growth.

### Patient Demand for Affordable Options

The demand for affordable insulin options is a critical driver of the insulin biosimilars market. Many patients face financial barriers when accessing insulin, leading to non-adherence to prescribed therapies. A survey conducted by the American Diabetes Association revealed that nearly 1 in 4 insulin users reported rationing their insulin due to cost concerns. This situation has prompted a push for more affordable alternatives, such as biosimilars, which can provide similar efficacy at a lower price point. As patients advocate for their rights to access necessary medications, the insulin biosimilars market is likely to see increased uptake, as healthcare providers respond to this demand by incorporating biosimilars into treatment regimens.

### Increased Investment in Biosimilar Development

Investment in the development of biosimilars is on the rise, driven by the potential for high returns in the insulin biosimilars market. Pharmaceutical companies are recognizing the lucrative opportunities presented by biosimilars, particularly as patents for original insulin products expire. The US market is witnessing a surge in research and development activities, with numerous companies entering the biosimilars space. According to the FDA, there are currently over 50 biosimilars approved for various indications, with insulin biosimilars being a key focus area. This influx of investment is expected to enhance competition, leading to improved product offerings and potentially lower prices for consumers. As more players enter the market, the insulin biosimilars market is poised for substantial growth.

## Future Outlook

The [Insulin Biosimilars Market](https://www.marketresearchfuture.com/reports/insulin-biosimilars-market-9775) is projected to grow at a 7.31% CAGR from 2025 to 2035, driven by increasing diabetes prevalence and cost-effective treatment options.

**New opportunities:**

- Development of patient-centric digital health platforms Expansion of biosimilar product lines targeting niche diabetes markets Strategic partnerships with healthcare providers for integrated care solutions

By 2035, the insulin biosimilars market is expected to achieve substantial growth and enhanced market presence.

## Segment Insights

### By Type: Long-acting biosimilars (Largest) vs. Rapid-acting biosimilars (Fastest-Growing)

In the US insulin biosimilars market, long-acting biosimilars hold the largest market share, catering to a significant portion of patients requiring consistent insulin delivery for extended periods. Rapid-acting biosimilars, while smaller in market share, are quickly gaining traction due to increasing patient demand for flexible and quick-acting insulin solutions. This distribution highlights the crucial role of patient needs and treatment preferences in shaping market dynamics. The growth trends in this segment are influenced by factors such as rising diabetes prevalence, technological advancements in insulin formulations, and increased healthcare awareness. The rapid-acting biosimilars segment is particularly poised for swift expansion, driven by the shift toward individualized treatment options and an increased focus on diabetes management. Meanwhile, long-acting biosimilars continue to be essential for stable insulin control, maintaining their dominance in the market.

Long-acting biosimilars (Dominant) vs. Rapid-acting biosimilars (Emerging)

Long-acting biosimilars have established a strong foothold in the US insulin biosimilars market, primarily due to their ability to provide a stable and prolonged insulin delivery, which is crucial for patients managing their blood glucose levels over extended periods. These biosimilars are commonly prescribed for their convenience and effectiveness in ensuring better glycemic control. On the other hand, rapid-acting biosimilars are emerging as a significant alternative, catering to patients who require quick insulin action for managing post-meal blood sugar spikes. This segment's rapid expansion is supported by innovations in formulation and an increasing recognition of the need for flexible treatment options that can adapt to varying patient lifestyles.

### By Indication: Type I Diabetes (Largest) vs. Type II Diabetes (Fastest-Growing)

The insulin biosimilars market is primarily driven by Type I and Type II diabetes indications. Type I diabetes holds a significant share of the market due to its longstanding prevalence and the essential nature of insulin in management, making it a dominant force. In contrast, Type II diabetes, characterized by lifestyle factors and increasing obesity rates, shows a rapidly growing market share as health awareness and treatment options expand in response to rising diagnoses. Growth trends indicate that Type II diabetes is the fastest-growing segment, propelled by a surge in the number of diagnosed patients, changing dietary habits, and increased accessibility to insulin therapies. The drive towards personalized medicine and innovative biosimilar products further supports growth in this segment. This trend highlights the evolving landscape of diabetes care, where effective management options are essential to meet patient needs.

Type I Diabetes (Dominant) vs. Type II Diabetes (Emerging)

Type I diabetes represents the dominant segment in the US insulin biosimilars market, reflecting the critical need for insulin therapy among affected patients. This segment is characterized by a stable patient base that relies heavily on insulin products for daily management of their condition. In contrast, Type II diabetes, while previously considered less severe, is emerging as a significant area of growth within the market. Factors contributing to its rise include an increase in adult obesity rates, lifestyle changes, and a broader acceptance of biosimilars among healthcare providers. As such, manufacturers are increasingly focusing their research and development efforts on this segment to supply effective and affordable treatment options, boosting overall market dynamics.

## Competitive Benchmarking

The insulin biosimilars market is characterized by a dynamic competitive landscape, driven by increasing demand for affordable diabetes management solutions and the growing prevalence of diabetes in the US. Key players such as Sanofi (FR), Mylan (US), and Amgen (US) are strategically positioning themselves through innovation and partnerships. Sanofi (FR) has focused on expanding its biosimilar portfolio, while Mylan (US) emphasizes local manufacturing to enhance supply chain efficiency. Amgen (US) is leveraging its strong R&D capabilities to develop next-generation biosimilars, collectively shaping a competitive environment that prioritizes accessibility and innovation.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain resilience. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Sandoz (CH) and Teva (IL) suggests a trend towards consolidation, as these firms seek to optimize their operations and enhance their competitive positioning.
In October Sanofi (FR) announced a strategic partnership with a leading technology firm to enhance its biosimilar development processes through advanced data analytics. This collaboration is expected to streamline R&D efforts, potentially reducing time-to-market for new products. Such initiatives indicate a shift towards integrating technology in drug development, which may provide Sanofi with a competitive edge in the rapidly evolving market.
In September Mylan (US) launched a new biosimilar product aimed at increasing patient access to insulin therapies. This move not only reinforces Mylan's commitment to affordability but also positions the company as a key player in addressing the rising healthcare costs associated with diabetes management. The introduction of this product is likely to enhance Mylan's market share and strengthen its brand reputation among healthcare providers.
In August Amgen (US) expanded its manufacturing capabilities by investing in a new facility dedicated to biosimilar production. This strategic investment is anticipated to bolster Amgen's production capacity and improve supply chain reliability, which is crucial in meeting the growing demand for insulin biosimilars. Such expansions reflect a broader trend of companies prioritizing operational efficiency and scalability in their business models.
As of November the competitive trends in the insulin biosimilars market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing innovation and market reach. Looking ahead, the competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative solutions, and robust supply chain management, ultimately benefiting patients and healthcare systems alike.

## Recent News & Developments

Recent developments in the US Insulin Biosimilars Market indicate a growing focus on increasing accessibility to insulin products. In August 2023, Eli Lilly announced the launch of a new biosimilar insulin product, which is aimed at improving affordability for patients. Merck has also been making strides in the market, reflecting a competitive atmosphere as companies strive to innovate and capture market share. Furthermore, Novartis has been actively engaging in partnerships and collaborations to enhance its biosimilar portfolio, signifying an evolving landscape. The market's growth is evident, with valuations surging due to heightened demand for cost-effective diabetes treatments.

In March 2022, the FDA's approval of multiple biosimilar insulin products marked a significant achievement, contributing to increased competition among major players such as Biocon, Sandoz, and Teva.

Additionally, in September 2022, Boehringer Ingelheim and Fresenius Kabi announced a strategic partnership focusing on insulin biosimilars, thereby solidifying their positions in the market. Overall, the competitive dynamics and recent developments reflect a robust evolution of the US Insulin Biosimilars Market, emphasizing innovation and patient-centered approaches.

## Report Scope

| MARKET SIZE 2024 | 1.26(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1.35(USD Million) |
| MARKET SIZE 2035 | 2.74(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.31% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Sanofi (FR), Boehringer Ingelheim (DE), Mylan (US), Sandoz (CH), Teva (IL), Fresenius Kabi (DE), Celltrion (KR), Amgen (US), Roche (CH) |
| Segments Covered | Type, Indication |
| Key Market Opportunities | Emerging regulatory frameworks enhance access and affordability in the insulin biosimilars market. |
| Key Market Dynamics | Regulatory advancements and competitive pricing strategies drive growth in the insulin biosimilars market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US insulin biosimilars market in 2024?**
A: The overall market valuation was $1.26 Million in 2024.

**Q: What is the projected market valuation for the US insulin biosimilars market by 2035?**
A: The projected valuation for 2035 is $2.74 Million.

**Q: What is the expected CAGR for the US insulin biosimilars market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 7.31%.

**Q: Which companies are considered key players in the US insulin biosimilars market?**
A: Key players include Sanofi, Boehringer Ingelheim, Mylan, Sandoz, Teva, Fresenius Kabi, Celltrion, Amgen, and Roche.

**Q: What were the valuations for rapid-acting biosimilars in 2024?**
A: The valuation for rapid-acting biosimilars was $0.38 Million in 2024.

**Q: What is the projected valuation for long-acting biosimilars by 2035?**
A: The projected valuation for long-acting biosimilars by 2035 is $1.36 Million.

**Q: How do the valuations for Type I and Type II diabetes biosimilars compare in 2024?**
A: In 2024, both Type I and Type II diabetes biosimilars had valuations of $0.63 Million.

**Q: What is the expected growth trend for premixed biosimilars from 2024 to 2035?**
A: The expected growth trend for premixed biosimilars indicates a rise from $0.25 Million in 2024 to $0.55 Million by 2035.

**Q: What segment of the US insulin biosimilars market shows the highest projected growth by 2035?**
A: The segment of long-acting biosimilars shows the highest projected growth, reaching $1.36 Million by 2035.

**Q: What does the market data suggest about the future of insulin biosimilars in the US?**
A: The market data suggests a robust growth trajectory, with an increase in valuation from $1.26 Million in 2024 to $2.74 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-insulin-biosimilars-market-19680*